Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI-4000 in Axillary Hyperhidrosis
NCT03024255Phase 2Completed
- Sponsor
- Botanix Pharmaceuticals
- Start
- Dec 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of sofpironium in primary axillary hyperhidrosis (PAH), sponsored by Botanix Pharmaceuticals. Started Dec 2016; status: completed.
02
Drugs
sofpironium
03
Conditions
primary axillary hyperhidrosis (PAH)
Beyond the preview
Go deeper on NCT03024255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03024255.